Neoplasm Reports in Food and Drug Administration Adverse Event Reporting System Following Angiotensin Receptor Blocker Recalls
- 1 August 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 14 (8) , e007476
Abstract
Background: A worldwide voluntary recall of valsartan in July 2018 due to the potential carcinogen N-nitrosodimethylamine received extensive media and public attention. This was followed by more Food and Drug Administration (FDA) recalls regarding other contaminated ARB (angiotensin receptor blocker) products. Our study investigated the association between the FDA recalls and ARB neoplasm adverse events (AEs) reported to the FDA adverse event reporting system. Methods: In this cross-sectional study, data were retrospectively collected from the FDA adverse event reporting system database from January 2015 to December 2019. Reporting odds ratios (RORs) were estimated to detect signals of association between ARBs (valsartan, irbesartan, and losartan) and reported neoplasm AEs using negative (amoxicillin and sertraline) and positive (omeprazole and ranitidine) control exposures. The χ 2 was used to compare categorical variables. Results: A total of 2 181 524 AEs, including 10 461 nonmetastatic neoplasm AEs were analyzed. Monthly RORs (95% CI) of valsartan-associated neoplasms versus controls (ROR*: valsartan/negative exposures; ROR†: valsartan/omeprazole; and ROR‡: valsartan/ranitidine) showed the highest signals after the recall date in July 2018 (7.64 [4.78–12.19]*; 4.77 [3.36–6.79]†; 4.13 [2.50–6.84]‡) and August 2018 (7.87 [5.19–11.94]*; 5.65 [4.12–7.75]†; and 7.20 [4.46–11.63]‡). In contrast, the highest cancer signals for the irbesartan and losartan recalls detected in March 2019 (4.80*; 4.06†; and 3.38‡) and April 2019 (3.63*; 3.69†; and 2.52‡) respectively, were lower. One-year postrecall reported neoplasm AEs were ≈2-fold higher for valsartan than irbesartan (OR, 1.77 [95% CI, 1.47–2.13], P P <0.0001). Although all ARBs had the same nitrosamine contamination, we found 1-year postrecall versus prerecall cancer signals for valsartan were 3-fold higher versus control exposures, while the changes in RORs for irbesartan and losartan were only 20-30% higher. Conclusions: Significantly more postrecall neoplasms were reported for valsartan, with higher valsartan-associated cancer signals compared with irbesartan and losartan, although they all contained the same carcinogenic contaminant. Extensive media coverage of the FDA valsartan recall may have alarmed patients and generated these abrupt, biologically infeasible cancer signals.Keywords
This publication has 30 references indexed in Scilit:
- Data Mining of the Public Version of the FDA Adverse Event Reporting SystemInternational Journal of Medical Sciences, 2013
- Use of antidepressants and the risk of breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2012
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 UpdateJACC, 2011
- N-nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)–Norfolk StudyThe American Journal of Clinical Nutrition, 2011
- Negative ControlsEpidemiology, 2010
- Antibiotics and Risk of Breast Cancer: Up to 9 Years of Follow-up of 2.1 Million WomenCancer Epidemiology, Biomarkers & Prevention, 2006
- Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UKGut, 2006
- High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N‐nitrosodimethylamine and N‐nitrosodiethylamine in mice and humansMolecular Carcinogenesis, 1993
- Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potentialMutation Research/Genetic Toxicology, 1991
- Carcinogenesis in rats by nitrosodimethylamine and other nitrosomethylalkylamines at low dosesCancer Letters, 1984